Carrier screening for cystic fibrosis

A number of different models of CF carrier screening have now been tested in pilot trials. Apart from opportunistic and cascade testing (which are strictly speaking not true forms of screening), the major programmes have been directed either to young adults in primary care or to pregnant women in antenatal clinics. Only in the latter form of screening has sufficient data been collected to allow conclusions to be reached on the optimum mode of delivery. It seems very probable that when CF carrier screening passes into routine service, it will be the antenatal couple model that is used.     

Neonatal lung function following mid-trimester amniocentesis

Three hundred and fifty-four women who underwent midtrimester genetic amniocentesis were matched for age, parity, indication, and smoking history, with an equivalent number of women who had declined the procedure, for the purpose of comparing the neonatal respiratory status of their offspring. There was no evidence that the infants exposed to genetic amniocentesis were compromised.     

PBNA及其同分异构体PANA在小鼠ICR系中致癌性的比较研究

对幼ICR雄性小鼠多次皮下注射PANA或它的同分异构体PANA的二甲基亚砜溶液,总剂量432mg,实验周期在10个月左右时均能引起显著高于对照组动物的恶性肿瘤.PANA诱发小鼠肿瘤可能存在剂量——反应关系.PBNA和PANA诱发肿瘤率相似,均以肺癌为主,但明显有不同的亲器官性.实验结果提示二者的致癌机理可能不是由于形成相应的萘胺所致.PANA对动物有致癌性,在国内外尚未见有报道.